Polygoni Hydropiperis Herba veterinary-grade API is distributed as a dried milled aerial-herb powder or as a spray-dried water-ethanol extract. No harmonised Ph. Eur. or USP monograph specific to this botanical material is applied by default; identity, loss on drying, total ash, microbial enumeration, and marker content are controlled by the supplier specification, the importing-country veterinary pharmacopoeia, and the marketing authorisation dossier. The material is formulated into tablets, hard capsules, aqueous injection, feed premix, soluble powder, granules, and oral solutions. Processing behaviour is determined by residual moisture, particle-size distribution, fibre content, and water-soluble tannin-flavonoid fraction rather than by a single isolated molecule. Because the API is botanical, the relationship between added quantity and finished-product performance is route-specific. Each downstream application below is treated as a separate manufacturing problem.

During direct-compression tablet manufacturing, the primary limitation is fibre elasticity. Sieving through a 60-mesh (250 µm) stainless steel screen is the first operation; lignified stem fragments above that size cause weight variation and punch face wear on rotary presses. The API is mixed with microcrystalline cellulose, dicalcium phosphate dihydrate, and sodium starch glycolate in a bin blender operating at 12–18 rpm for 20–30 minutes. If the API bulk density is below 0.45 g/mL, hopper flow becomes erratic and the compression run stops. A practical pilot range is 8 % w/w to 25 % w/w API when the milled powder has been dried to <5.0 % w/w residual moisture. Higher API loads can be used after wet granulation, but direct compression above 25 % w/w usually produces capping and lamination because the compressibility of the botanical matrix is poor. Magnesium stearate is limited to 0.5 % w/w and is added as the final lubricant only after the API and disintegrant are pre-mixed; otherwise the powder becomes hydrophobic and disintegration slows. The tablet press is run at 30–50 rpm on a 10-station instrumented rotary machine with 19 mm concave tooling. Tablet hardness is held at 6–8 kp and friability below 0.8 % before aqueous film coating. The finished tablet is tested under Ph. Eur. 2.9.1 for disintegration, Ph. Eur. 2.9.3 for dissolution when specified by the dossier, and Ph. Eur. 2.9.5 for uniformity of mass. Residual moisture is monitored with a halogen moisture analyzer; if moisture rises above 5.0 % w/w, tablet hardness drops and picking occurs on embossed punches. Pre-compression force is set at 2.0–4.0 kN and main compression force at 8–15 kN for a 19 mm round flat-faced bevel-edge tooling set. The exact force settings depend on punch fill depth and blend compressibility. Published data for this specific configuration is limited; the above parameters are pilot starting points rather than pharmacopoeial limits.

Premix Carrier Selection Under EU Feed Hygiene Regulation 183/2005/EC

In a feed premix line, two-step dilution is used to prevent segregation of the low-bulk-density botanical powder. The API is first extended onto precipitated silica or rice hull powder at a 1:3 to 1:5 ratio in a ribbon mixer to improve flow and reduce dusting. The resulting intermediate is added to a calcium carbonate or corncob carrier containing vitamins and trace minerals in a horizontal paddle mixer. A practical final premix concentration is between 0.5 kg and 5.0 kg API per tonne of finished feed when the premix is intended for top-dressing at 1 % of daily ration; however, published data for this specific plant extract is limited and the dosage must be derived from the veterinary marketing authorisation. Mixing time is set by coefficient of variation; in production, a 15-minute blend in a 1000-litre ribbon mixer with a 1:1.5 working volume is usually sufficient to reach a CV below 5 %, provided the API has been sieved and dried to <7.0 % moisture. Compliance is anchored to Regulation (EC) No 183/2005/EC Annex II, which requires HACCP-based hygiene control for feed business operators, and to Directive 2002/32/EC for undesirable substances, including heavy metals and dioxins. Retention samples are tested for lead, cadmium, arsenic, and aflatoxin B1, with acceptance limits set by the importing market, not by the API supplier. The terminal product is a dust-free, free-flowing premix packed in 25-kg paper bags with an inner polyethylene liner.

Why Do Injectable Aqueous Solutions Fail at Low pH and High Particulate Load?

For injectable aqueous solutions, the solvent choice is water-based rather than oil-based because the dry extract contains water-soluble polyphenols. The extract is dissolved or dispersed in Water for Injection at 5–10 mg/mL, but the exact concentration must be justified by stability data because tannin-rich extracts can form haze and sediment when the pH is lowered below 4.0. Published stability data for this specific configuration is limited. The bulk solution is adjusted to pH 5.5–6.5 using dilute sodium hydroxide or citric acid, then cooled to 20–25 °C before filtration. A two-stage filtration train is used: a 0.45 µm polyethersulfone capsule followed by a 0.22 µm sterilising-grade membrane. Directly using a 0.22 µm filter without pre-filtration blocks the membrane after 50–100 L/m² due to colloid loading. The filtered solution is filled into Type I glass vials in a Grade C background with Grade A local protection, consistent with EU GMP Annex 1 and ISO 14644-1 cleanroom classification, then terminally sterilised at 121 °C for 15 minutes.

The injectable route is limited by particulate matter from hay-like fibres and by endotoxin from naturally occurring Gram-negative bacteria on the aerial herb. Endotoxin reduction prior to formulation is performed using ultrafiltration or ion exchange; heat alone does not inactivate endotoxin. Because the extract contains redox-active polyphenols, the solution is blanketed with nitrogen and protected from light during compounding and filling. Filter capacity is batch-critical. A small-scale trial recirculates the solution through a 0.45 µm capsule at 25 °C and records differential pressure for 8 hours. If the pressure exceeds 2.0 bar before the target batch volume is filtered, the extract lot is either rejected or pre-clarified by centrifugation at 5000 rpm for 10 minutes. This step removes the high-fibre fraction before the sterilising filter. Published data for this specific configuration is limited; filter-loading trials are required for each new supplier lot. The terminal vial or ampoule product is released only after a 14-day sterility incubation and visual inspection under Ph. Eur. 2.9.20. Release tests for a pilot aqueous injection batch are listed below.

Because the spray-dried extract is hygroscopic, drinking-water soluble powders require a low-moisture, fast-dispersing carrier. A dry blend of 10–20 % w/w API, 70–80 % glucose monohydrate, and 2–5 % colloidal silicon dioxide is prepared in a twin-shell blender. The silica is critical not only as anti-caking agent but also as a partition between hygroscopic extract particles; without it, the powder aggregates within 48 hours in a 25-kg fibre drum at 25 °C and 60 % relative humidity. The loading is limited by bulk density and the dose cup. If the bulk density falls below 0.35 g/mL, the volumetric dosing scoop becomes inaccurate. The finished soluble powder is packed in aluminium foil laminate pouches. When added to drinking water at 1 g/L, dispersion time is measured at 20–25 °C using a standard 1000 mL beaker; complete dispersion should occur within 2–3 minutes without foaming or sediment. The terminal product is administered via header tanks or proportioning pumps, so particle size of the dry blend is kept below 180 µm to avoid blocking proportioner valves. Compliance is based on Ph. Eur. 2.2.32 for loss on drying, Ph. Eur. 2.9.34 for bulk density, and the relevant national veterinary medicinal product regulation.

When Wet-Mass Extrusion-Spheronization Is Used for Oral Granules

If direct compression fails, wet granulation is selected as the route for oral granules. The API is premixed with microcrystalline cellulose and lactose monohydrate in a high-shear granulator, then wetted with a binder solution containing 5 % w/w povidone K30. The wet mass is extruded through a dome or radial extruder equipped with a 1.0–1.2 mm screen at a feed rate that keeps product temperature below 35 °C. The extrudate is transferred to a spheronizer with a grooved friction plate running at 600–900 rpm for 2–4 minutes; higher speeds produce dense pellets but also generate frictional heat that can darken the botanical extract. The wet pellets are dried in a fluid-bed dryer with inlet air at 50–60 °C until loss on drying is below 4.0 %. The final granules are sieved between 0.8 mm and 1.6 mm; fines below 0.8 mm are recycled into the next wet mass. The terminal product is filled into aluminium sachets at 25 g per sachet. Granule hardness is controlled by spheronization time and moisture endpoint, not by compression. Analytical release includes particle-size distribution specified in the dossier, loss on drying under Ph. Eur. 2.2.32, and microbial enumeration under Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13.

Across high-speed dosator-type capsule fillers, the wide particle-size distribution of the milled herb is the main yield constraint. The powder is first milled with a pin mill and sieved through a 40-mesh screen; the retained fraction is usually 3–8 % and is removed. The base powder is blended with 60–70 % lactose monohydrate and 0.5 % hydrophobic fumed silica in a V-blender. The target fill weight is set by the capsule size and the tapped density of the blend; for a size 0 capsule, a fill weight of 350–400 mg is typical when the tapped density is 0.50–0.65 g/mL. The powder mixture is filled on a dosator-type capsule machine operating at 30,000–50,000 capsules/hour; dosator nozzles are polished and checked for sticking at least every 4 hours because botanical residues accumulate on the inner walls. Capsule shells are conditioned at 40–50 % relative humidity for 24 hours before filling to prevent brittleness; the fill room is maintained at <35 % relative humidity to keep the blended powder flowable. The filled capsules are dedusted and checked for sink/float behaviour in 0.1 M hydrochloric acid at 37 °C to detect gross segregation; if filled capsules float due to air pockets, the compression ratio in the dosator must be increased. The finished capsules are tested under Ph. Eur. 2.9.1 for disintegration and Ph. Eur. 2.9.5 for mass uniformity. The capsule route is preferred over tablets when the API is non-compactible or when the formulation contains oily extracts.

Soluble Oral Solutions and Ethanol-Free Preservative Systems

For oral solutions intended for food-producing species, ethanol-free preservative systems are preferred because ethanol is restricted in many markets. The extract is dissolved in purified water with 10–20 % propylene glycol and 0.1–0.2 % potassium sorbate or sodium benzoate. The solution is adjusted to pH 5.0–6.0 with citrate buffer to reduce oxidation of polyphenols. The manufacturing vessel is a closed stainless-steel mixing tank with a bottom-mounted stirrer and nitrogen overlay. The solution is filtered through a 10 µm stainless steel filter to remove undissolved chlorophyll and waxes, then through a 5 µm polypropylene capsule. Filling is performed by a peristaltic pump into amber PET or glass bottles. The terminal product is a clear-to-slightly-opalescent liquid with a shelf life limited by sedimentation and microbial challenge; preservative efficacy is tested under Ph. Eur. 5.1.3. The solution is labelled for oral administration only, not for injection, because it is not sterile and not endotoxin-controlled. Release tests include pH under Ph. Eur. 2.2.3, density under Ph. Eur. 2.2.5, and total viable aerobic count under Ph. Eur. 2.6.12.